News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biodesix, Inc. Announces Results in Phase III Lung Cancer Diagnostic Study; First Prospective Biomarker-Stratified Validation Study in Oncology



6/3/2013 12:29:20 PM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc., a fully integrated molecular diagnostics company dedicated to personalizing medicine, today announced results of the recently completed phase III clinical trial for its VeriStrat® test. Data confirms that the non-invasive, blood-based protein diagnostic is predictive of differential treatment outcomes between two types of therapies for second-line treatment of advanced non-small cell lung cancer: chemotherapy or the targeted drug erlotinib (Tarceva®).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES